Virtual test kits for predicting harmful effects triggered by drugs and chemicals mediated by specific proteins

Altex

Volumn 22, Issue 3, 2005, Pages 123-134

  Vedani, Angelo ^a   Dobler, Max ^a   Lill, Markus A ^a  

^a Biographics Laboratory 3R   (Switzerland)

Author keywords

In silico toxicology; Multi dimensional QSAR; Reducing animal testing; Virtual experiments; Virtual test kits

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; CHEMICAL AGENT; CYTOCHROME P450 3A4; DRUG; ESTROGEN RECEPTOR; MIBOLERONE; PROTEIN; XENOBIOTIC AGENT;

ANALYTICAL EQUIPMENT; ARTICLE; BINDING AFFINITY; CARCINOGENICITY; COMPUTER MODEL; COMPUTER PROGRAM; DANGEROUS GOODS; DEVELOPMENTAL DISORDER; DRUG METABOLISM; HEALTH HAZARD; HUMAN; IMMUNOTOXICITY; MONTE CARLO METHOD; NONHUMAN; PHYSICAL CHEMISTRY; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPRODUCTIVE TOXICITY; SIMULATION; SKIN TOXICITY; TOXICITY; TOXICITY TESTING; VALIDATION PROCESS;

CYTOCHROME P-450 ENZYME SYSTEM; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REAGENT KITS, DIAGNOSTIC; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, THYROID HORMONE; USER-COMPUTER INTERFACE;

EID: 27144507066     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Borman, S. (1990). Cros, A. F. A., PhD Thesis, University of Strasbourg, 1863 cited from "New QSAR techniques eyed for environmental assessments". Chem. & Eng. News 19, 20-23.
2. Carlsen, E., Giwercman, A., Keiding, N. and Skakkebaek, N. E. (1992). Evidence for decreasing quality of semen during past 50 years. Br. Med. J. 305, 609-613.
3. Colborn, T. (1995). Environmental estrogens: health implications for humans and wildlife. Environ. Health Perspect. 103 (suppl. 7), 135-136.
4. Colborn, T., von Saal, F. S. and Soto, A. M. (1993). Developmental effects of endocrine-disrupting chemicals in wildlife and humans (see comments). Environ. Health Perspect. 101, 378-384.
5. Cramer, C. J. and Truhlar, D. G. (1992). AM1-SM2 and PM3-SM3 parametrized SCF solvation models for free energies in aqueous solution. J. Comp.-Aided Molec. Design 6, 629-666.
6. Cramer, R. D. III, Patterson, D. E. and Bunce, J. D. (1988). Comparative Molecular Fields Analysis (CoMFA). I. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110, 5959-5967.
7. Cramer, R. D. III and Milne, M. (1979). The lattice model: a general paradigm for shape-related structure-activity correlations. Abstracts of papers of the Am. Chem. Soc. Meeting, April 1979, COMP 44.
8. Cronin, M. (2003). A toxic gamble. Chemistry and Industry 4, 13-14.
9. Dibb, S. (1995). Swimming in a sea of estrogens, chemical hormone disrupters. The Ecologist 25, 27-31.
10. Dobler, M., Lill, M. A. and Vedani, A. (2003). From crystal structures and their analysis to the in silico prediction of toxic phenomena. Helv. Chim. Acta 86, 1554-1568.
11. Ekins, S., Bravi, G., Binkley, S. et al. (1999). Three- and four-dimensional quantitative structure-activity relationship analyses of cytochrome P450 3A4 inhibitors. J. Pharmacol. Exp. Ther. 290, 429-438.
12. Feldman, D. and Krishnan, A. (1995). Estrogens in unexpected places: Possible implications for researchers and consumers. Environ. Health Perspect. 103 (suppl. 7), 129-133.
13. Fischer, B. (2000). Receptor-mediated effects of chlorinated hydrocarbons. Andrologia 32, 279-283.
14. Free, S. M. and Wilson, J. W. (1964). A mathematical contribution to structure-activity studies. J. Med. Chem. 7, 395-399.
15. Guillette, L. J., Crain D. A., Rooney, A. A. and Pickford, D. B. (1995). Organization versus activation: the role of endocrine disrupting contaminants EDCs during embryonic development in wildlife. Environ. Health Perspect. 103 (suppl. 7), 157-164.
16. Gustaffson, J. A. (1995). Receptor-mediated toxicity. Toxicol. Lett. 135, 465-470.
17. Hammet, L. P. (1935). Reaction rates and indicator acidities. Chem. Rev. 17, 67-79.
18. Hampson, A. J. and Grimaldi, M. (2002). 12-hydroxyeicosatetrenoate (12-HETE) attenuates AMPA receptor-mediated neurotoxicity: Evidence for a G-protein coupled HETE receptor. J. Neurosci. 22, 257-264.
19. Hansch, C. and Fujita, T. (1964). ρ-σ-π Analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 86, 1616-1626.
20. Hansch, C. and Clayton, J. M. (1973). Lipophilic character and biological activity of drugs II: The parabolic case. J. Pharm. Sci. 62, 1-21.
21. Hoare, S. A., Jobling, S., Parker, M. G. et al. (1994). Environmental persistent alkylphenolic compounds are estrogenic. Endocrinology 135, 175-182.
22. Hopfinger, A. J., Wang, S., Tokarski, J. S. et al. (1997). Construction of 3D-QSAR models using 4D-QSAR analysis formalism. J. Am. Chem. Soc. 119, 10509-10524.
23. Kavlock, R. J., Daston, G. P., DeRosa, C. et al. (1996). Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshop. Environ. Health Perspect. 104 (Suppl. 4), 715-740.
24. Korach, K. S., Levy, L. A. and Sarver, P. J. (1987). Estrogen receptor stereochemistry: receptor binding and hormonal responses. J. Steroid Biochem. 27, 281-290.
25. Kubinyi, H. (2002). From narcosis to hyperspace: The history of QSAR. Quant. Struct.-Act. Relat. 21, 348-356.
26. Kubinyi, H., Folkers, G. and Martin, Y. C. (1998a). 3D-QSAR in drug design. Volume 2. Ligand-protein complexes and molecular similarity, Kluwer/ESCOM, Dordrecht 1998; also published as Persp. Drug Disc. Design 9-11, 1-416.
27. Kubinyi, H., Folkers, G. and Martin, Y. C. (1998b). 3D-QSAR in drug design. Volume 3. Recent advances, Kluwer/ESCOM, Dordrecht 1998; also published as Persp. Drug Disc. Design 12-14, 1-352.
28. Kubinyi, H. (ed.) (1993). 3D-QSAR in drug design. Theory, methods and applications. Leiden: ESCOM Science Publishers B.V.
29. Landers, J. P. and Bunce, N. J. (1991). The Ah receptor and the mechanism of dioxin toxicity. Biochem. J. 276, 173-287.
30. Lien, E. J. (1975). Structure-absorption-distribution relationships. In E. J. Ariëns (ed.), Drug Design (Volume V, 81-132). New York: Academic Press.
31. Lill, M. A., Winiger, F., Vedani, A. and Ernst, B. (in press). Impact of induced fit on ligand binding to the androgen receptor: A multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J. Med. Chem.
32. Lill, M. A., Dobler, M. and Vedani, A. (submitted). Prediction of small-molecule binding to cytochrome P450 3A4: Flexible docking combined with multidimensional QSAR. Chem. Med. Chem.
33. Lill, M. A., Vedani, A. and Dobler, M. (2004). Raptor - combining dual-shell representation, induced-fit simulation and hydrophobicity scoring in receptor modeling: Application towards the simulation of structurally diverse ligand sets. J. Med. Chem. 47, 6174-6186.
34. Lukasink, K. and Pitkanen, A. (2000). GABA(A)-mediated toxicity of hippocampal neurons in vitro. J. Neurochem. 74, 2445-2454.
35. McLachlan, J. A. and Arnold, S. F. (1996). Environmental estrogens. Am. Sci. 84, 452-461.
36. Mohamadi, F., Richards, N. G. J., Guida, W. C. et al. (1990). MacroModel - An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 11, 440-467.
37. OECD (2003). http://webdomino1.oecd.org/comnet/env/models.nsf.
38. Okey, A. B., Riddick, D. S. and Harper, P. A. (1994). The Ah receptor: Mediator of the toxicity of 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol. Lett. 70, 1-22.
39. Oliver, J. D. and Roberts, R. A. (2002). Receptor-mediated hepatocarcinogenesis: role of hepatocyte proliferation and apoptosis. Pharmacol. Toxicol. 91, 1-7.
40. Putzrath, R. M. (1997). Estimating relative potency for receptor-mediated toxicity: Re-evaluating the toxicity equivalence factor (TEF) model. Reg. Tox. Pharmacol. 25, 68-78.
41. Rappe, C. (1993). Environmental concentrations and ecotoxicological effects of PCDDs, PCD Fs and related compounds. Organohalogen Compounds, Dioxin 12, 163-170.
42. Rihova, B. (1998). Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 29, 273-289.
43. Rymer, D. L. and Good, T. A. (2001). The role of protein activation in the toxicity of amyloidogenic Aβ (1- 40), Aβ (25-35), and bovine calcitonin. J. Biol. Chem. 276, 2523-2530.
44. Safe, S. and Krishnan, K. (1995). Cellular and molecular biology of Aryl hydrocarbon (Ah) receptor-mediated gene expression. In D. H. Degen, J. P Seiler and P. Bentley (eds.), Archives of Toxicology (Suppl. 17, 116-124), Berlin: Springer Verlag.
45. Safe, S. (1990). Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs) and related compounds: Environmental and mechanistic considerations which support the development of toxic equivalency factors (TEFs). CRC Crit. Rev. Toxicol. 21, 51-88.
46. Shiau, A. K., Barstad, D., Loria, P. M. et al. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen endogenous estrogen 17β-estradiol (E2) and the synthetic nonsteroidal estrogen diethylstilbestrol (DES). Cell 95, 927-937.
47. Swanson, H. I. and Bradfield, C. A. (1993). The Ah-Receptor: Genetics, structure and function. Pharmacogenetics 3, 213-230.
48. Swiss National Science Foundation (2001). http://www.nrp50.ch.
49. Tanaka, E. (1998). Clinically important pharamcokinetic drug-drug interactions: Role of cytochrome P450 enzymes. J. Clin. Pharm. Therap. 23, 403-416.
50. Topliss, J. G. and Costello, R. J. (1972). Chance correlations in structure-activity studies using multiple regression analysis. J. Med. Chem. 15, 1066-1068.
51. Ungerer, S. H. and Hansch, C. (1973). On model building in structure-activity relationships. A reexamination of adrenergic blocking of β-halo-β-arlyalkylamines. J. Med. Chem. 16, 745-749.
52. US Government (1996a): Safe Drinking Water Act Amendment. Public Law 104-182 (Section 136), http://www.epa.gov.safewater/sdwa/index.html.
53. US Government (1996b): Food Quality Protection Act. Public Law 104-170 (Section 408), http://www.fda.gov/opacom/laws/foodqual/fqpatoc.htm.
54. Vedani, A., Dobler, M. and Lill, M. A. (in press). In silico prediction of harmful effects triggered by drugs and chemicals. Toxicol. Appl. Pharmacol.
55. Vedani, A., Dobler, M. and Lill, M. A. (2005b). Combining protein modeling and 6D-QSAR - Simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 48, 3700-3703.
56. Vedani, A., Dollinger, H., Hasselbach, K.-M. et al. (2005a). Novel ligands for the chemokine receptor-3 (CCR3): A receptor modeling study based on 5D-QSAR. J. Med. Chem. 48, 1515-1527.
57. Vedani, A. and Dobler, M. (2003). Internet laboratory for predicting harmful effects triggered by drugs and chemicals - A progress report. ALTEX 20, 85-91.
58. Vedani, A. and Dobler, M. (2002). 5D-QSAR: The key for simulating induced fit? J. Med. Chem. 45, 2139-2149.
59. Vedani, A., Briem, H., Dobler, M. et al. (2000). Multiple conformation and protonation-state representation in 4D-QSAR: The neurokinin-1 receptor system. J. Med. Chem. 43, 4416-4427.
60. Vedani, A., McMasters, D. R. und Dobler, M. (1999). Genetische Algorithmen im 3D-QSAR: Verwendung multipler Wirkstofforientierungen zur verbesserten Voraussage der Toxizität. ALTEX 16,9-14;
61. Vedani, A., McMasters, D. R. und Dobler, M. ALTEX 16, 140-143.
62. Vedani, A. and Dobler, M. (2001). Internet laboratory for predicting harmful effects triggered by drugs and chemicals. ALTEX 18, 110-114.
63. Vedani, A., Dobler, M. and Zbinden, P. (1998). Quasi-atomistic receptor surface models: A bridge between 3-D QSAR and receptor modeling. J. Am. Chem. Soc. 120, 4471-4477.
64. Vedani, A. and Huhta, D. W. (1991). An algorithm for the systematic solvation of proteins based on the directionality of hydrogen bonds. J. Am. Chem. Soc. 113, 5860-5862.
65. Vedani, A. and Huhta, D. W. (1990). A new force field for modeling metalloproteins. J. Am. Chem. Soc. 112, 4759-4767.
66. White paper on the strategy for a future chemicals policy (2003). Cf. http://europa.eu.int/comm/environment/chemicals/whitepaper.htm.
67. Whitlock jr., J. P. (1993). Mechanistic aspects of dioxin action. Chem. Res. Toxicol. 6, 754-763.
68. Zubay, G. L., Parson, W. W. and Vance, D. E. (1995). Principles of Biochemistry. Dubuque, USA: Wm. C. Brown Communications, Inc.
69. Zumstein, M. (2005). Establishing a quantitative structure-activity relationship for the α/β selectivity of the thyroid receptor. M.Sc. thesis, University of Basel.